A review on impact of pegylation on biopharmaceuticals

Sachin Gundecha; Satish Shirolkar; Sanjivani Deshkar; Sohan Chitlange; Sunil Shewale; Rahul Arun Jagtap

doi:10.53730/ijhs.v6nS3.7477

Authors

Sachin Gundecha
sachingundecha@yahoo.co.in
Department of Pharmaceutics, Research Scholar Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Savitribai Phule Pune University, Maharashtra (India) and Gennova Biopharmaceutical Limited, Hinjawadi, Pune
Satish Shirolkar Department of Pharmaceutics, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Savitribai Phule Pune University, Maharashtra (India)
Sanjivani Deshkar Department of Pharmaceutics, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Savitribai Phule Pune University, Maharashtra (India)
Sohan Chitlange Principal, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Savitribai Phule Pune University, Maharashtra (India)
Sunil Shewale Research Scholar, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, University of Pune. Maharashtra (India)
Rahul Arun Jagtap Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, University of Pune. Maharashtra (India)

Keywords:

pegylation, biopharmaceutical, covalent, conjugation, PEG reagent

Abstract

Covalent conjugation of polyethylene glycol (PEG) molecules to biopharmaceutical molecules is known to increase the pharmacological and medicinal characteristics of proteins and other big molecules and has been utilized effectively in 12 authorized medications. PEG reagents with straight and branched chains up to 40 kDa were utilized with a variety of PEG derivatives with varied linker chemistries. This article discusses the characteristics of PEG, the history and evolution of PEGylation chemistry, and examples of PEGylated pharmaceuticals with a proven track record. They prefer to employ bigger PEG polymers and complicated PEG structures, although they use extremely pure and well-characterized PEG reagents. The preclinical toxicity data for PEG in PEGylated biologics that have been authorized are summarised. Microscopically detected cell vacuolization in phagocytes, which is connected to the biological function of absorption and elimination of particles and macromolecules from blood and tissues. It's possible. Side effects in toxicity tests typically relate to the active moiety of the medicine, not the PEG moiety, according to experience with commercially available PEGylated pharmaceuticals.

Downloads

Download data is not yet available.

References

Cristina C/O Polymasc Pharmac, 1988, EP0727438A2, Adducts of PEG and GM-CS, Europe, October 1988

Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA. To PEGylate or not to PEGylate: immunological properties of nanomedicine's most popular component, poly (ethylene) glycol, and its alternatives. Advanced drug delivery reviews. 2021 Dec 10:114079.

Turecek PL, Siekmann J. PEG–protein conjugates: nonclinical and clinical toxicity considerations. InPolymer-Protein Conjugates 2020 Jan 1 (pp. 61-101). Elsevier.

Kaith BS, Mittal H, Jindal R, Maiti M, Kalia S. environment benevolent biodegradable polymers: Synthesis, biodegradability, and applications. InCellulose fibers: bio-and nano-polymer composites 2011 (pp. 425-451). Springer, Berlin, Heidelberg.

Locatelli E. Synthesis and surface modification of silver and gold nanoparticles. Nanomedicine applications against Glioblastoma Multiforme.

Elliott VL, Edge GT, Phelan MM, Lian LY, Webster R, Finn RF, Park BK, Kitteringham NR. Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies. Molecular pharmaceutics. 2012 May 7;9(5):1291-301.

Lubich C. Characterization of potentially immunogenic properties of a novel PEGylated FVIII preparation (Doctoral dissertation).

https://www.tandfonline.com/doi/abs/10.1517/17425240802650568

Dehelean CA, Marcovici I, Soica C, Mioc M, Coricovac D, Iurciuc S, Cretu OM, Pinzaru I. Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy. Molecules. 2021 Jan;26(4):1109.

Wang L, Wang J, Gao X, Liang Z, Zhu B, Zhu L, Xu Y. A facile transesterification route to polysulfone-poly (ethylene glycol) amphiphilic block copolymers with improved protein resistance. Polymer Chemistry. 2014;5(8):2836-42.

Sundaram M, Priya P. Novel Bio-Hybrid Nanoscale Carriers Engineered for High Therapeutic Payload and Controllable Extended-Release Using Nucleic Acid Aptamers (Doctoral dissertation).

Binder U, Skerra A. PASylated Thymosin α1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology. International Journal of Molecular Sciences. 2021 Jan;22(1):124.

Belén LH, Rangel-Yagui CD, Beltrán Lissabet JF, Effer B, Lee-Estevez M, Pessoa A, Castillo RL, Farías JG. From synthesis to the characterization of site-selective PEGylated proteins. Frontiers in pharmacology. 2019 Dec 18;10:1450.

Chekhonin VP, Zhirkov YA, Gurina OI, Ryabukhin IA, Lebedev SV, Kasparov IA, Blinov DV, Dmitrieva TB. Polyethylene-glycosylated immunoliposomes specific for astrocytes. InDoklady Biochemistry and Biophysics 2003 Jul (Vol. 391, No. 1, pp. 236-239). Kluwer Academic Publishers-Plenum Publishers.

Lawrence PB, Price JL. How PEGylation influences protein conformational stability. Current opinion in chemical biology. 2016 Oct 1;34:88-94.

Pandey BK, Smith MS, Torgerson C, Lawrence PB, Matthews SS, Watkins E, Groves ML, Prigozhin MB, Price JL. The impact of site-specific PEGylation on the conformational stability and folding rate of the Pin WW domain depends strongly on PEG oligomer length. Bioconjugate chemistry. 2013 May 15;24(5):796-802.

Wilding KM, Smith AK, Wilkerson JW, Bush DB, Knotts IV TA, Bundy BC. The locational impact of site-specific PEGylation: streamlined screening with cell-free protein expression and coarse-grain simulation. ACS synthetic biology. 2018 Feb 16;7(2):510-21.

Vesting MM, Murphy CM, Fenselau C, Dedinas J, Doleman MS, Harrsch PB, Kutny R, Ladd DL, Olsen MA. Characterization of PEGated Superoxide Dismutase. techniques in Protein Chemistry III 1992 Jan 1 (pp. 477-485). Academic Press.

Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Advanced drug delivery reviews. 2002 Jun 17;54(4):459-76.

KINSTLER O. ET AL.: 'Mono¬N¬terminal poly(ethylene glycol)¬protein conjugates' ADV. DRUG DELIV. REV. vol. 54, no. 4, 2002, pages 477 ¬ 483

KNOSLI C. ET AL.: 'Polyethylene Glycol (PEG) Modification of Granulocyte¬Macrophage Colony Stimulating Factor (GM¬CSF) Enhances Neutrophil Priming Activity but not Colony Stimulating Activity' BR. J. HAEMATOL. vol. 82, no. 4, 1992, pages 654 ¬ 663,

MALIK F. ET AL.: 'Polyethylene Glycol (PEG)¬Modified Granulocyte¬Macrophage Colony¬Stimulating Factor (GM¬CSF) with Conserved Biological Activity' EXP. HEMATOL. vol. 20, no. 8, 1992, pages 1028 ¬ 1035

SHERMAN M.R. ET AL.: 'Conjugation of High¬Molecular Weight Poly(ethylene Glycol) to Cytokines: Granulocyte¬Macrophage Colony¬Stimulating Factors as Model Substrates' ACS SYMPOSIUM SERIES vol. 680, 1997, pages 155 ¬ 169

Bailon, Pascal; Won, Chee-Youb (2009). PEG-modified biopharmaceuticals. , 6(1), 1–16. doi:10.1517/17425240802650568

Veronese, Francesco M. (2009). PEGylated Protein Drugs: Basic Science and Clinical Applications || Enzymatic techniques for PEGylation of biopharmaceuticals. , 10.1007/978-3-7643-8679-5(Chapter 5), 75–88. doi:10.1007/978-3-7643-8679-5_5

Damodaran VB, Fee C. Protein PEGylation: An overview of chemistry and process considerations. European Pharmaceutical Review. 2010 Feb 3;15(1):18-26.